Free tool
FAERS Monitor: Myfembree
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214846 or its brand name (Myfembree, Estradiol, Norethindrone Acetate, Relugolix). Reports on generic versions are filed under their own applications.
Reports
1,516
Serious
162
11% of reports
Hospitalization
35
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- therapy interrupted472
- heavy menstrual bleeding233
- intermenstrual bleeding118
- headache74
- off label use72
- hot flush70
- alopecia68
- menstruation irregular62
- dysmenorrhoea60
- nausea51
- pain45
- drug ineffective40
- depression33
- inappropriate schedule of product administration32
- fatigue30
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 66 |
| 2022 | 241 |
| 2023 | 542 |
| 2024 | 481 |
| 2025 | 108 |
| 2026 | 78 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,643 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| heavy menstrual bleedingSignal | 233 | 368.8 | 327.1 | 82,936 |
| intermenstrual bleedingSignal | 118 | 299.2 | 251.1 | 34,053 |
| therapy interruptedSignal | 472 | 92.2 | 85.5 | 42,368 |
| dysmenorrhoeaSignal | 60 | 63.1 | 49.2 | 3,589 |
| menstruation irregularSignal | 62 | 32.2 | 25.2 | 1,841 |
| hot flushSignal | 70 | 12.9 | 10.3 | 758 |
| alopeciaSignal | 68 | 4.8 | 3.8 | 203 |
| inappropriate schedule of product administrationSignal | 32 | 2.5 | 1.7 | 27 |
| depressionSignal | 33 | 2.0 | 1.4 | 16 |
| headache | 74 | 1.6 | 1.3 | 18 |
| off label use | 72 | 1.1 | 0.9 | 1 |
| pain | 45 | 1.0 | 0.8 | 0 |
| nausea | 51 | 0.9 | 0.7 | 1 |
| fatigue | 30 | 0.5 | 0.4 | 12 |
| drug ineffective | 40 | 0.4 | 0.3 | 33 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.